Cancer immunotherapy using tumor-infiltrating lymphocytes.
Figlin
R A
RA
Bowyer Oncology Center, University of California, Los Angeles.
D016827:CD8 Antigens / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy*; D002469:Cell Separation / Q000379:methods; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000601:surgery / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D009392:Nephrectomy; D012074:Remission Induction; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000637:transplantation
D016827:CD8 Antigens; D007155:Immunologic Factors; D016898:Interferon-alpha; D007376:Interleukin-2